Coronary Angiography Devices Market Summary

• The Coronary Angiography Devices market is estimated at USD 13.47 billion in 2025 and is projected to reach USD 24.83 billion by 2034. Growth is anchored in the rising prevalence of cardiovascular disease, an expanding aging population, and rapid technological advancement in imaging, procedural guidance, and minimally invasive cardiac catheterization.
• The global Coronary Angiography Devices market is growing at a CAGR of 7.03% during the forecast period from 2026 to 2034.
• By product, the angiography systems segment dominated the Coronary Angiography Devices market with a 25% share in 2025.
• By technology, the X-ray angiography segment dominated the Coronary Angiography Devices market with a 52% share in 2025.
• By application, the diagnostics segment dominated the Coronary Angiography Devices market with a 58% share in 2025.
• By end-user, the hospitals segment dominated the Coronary Angiography Devices market with a 68% share in 2025.
• North America dominated the global Coronary Angiography Devices market revenue with a 35% share in 2025, representing the highest regional market share globally.

Coronary angiography devices are the specialized medical instruments and equipment used in coronary angiography, a minimally invasive cardiac catheterization procedure that uses X-ray imaging and contrast dye to visualize the coronary arteries and identify narrowed or blocked vessels, the hallmark of coronary artery disease. The same devices are frequently used for follow-on therapeutic procedures such as balloon angioplasty and stent placement. The product universe spans high-value capital equipment, namely fixed and mobile angiography systems and hybrid cath-lab platforms, and high-volume consumables, including angiography catheters, guidewires, balloons, and vascular closure devices (VCDs). Because every procedure requires disposables while each cath lab requires a capital system backed by service contracts and software upgrades, the market combines one-time equipment revenue with recurring consumable and service revenue. The market is organized by product across angiography systems, catheters, VCDs, balloons, guidewires, and others; by technology across X-ray, CT, and MR angiography; by application across diagnostics and therapeutics; by end-user across hospitals, diagnostic centers, and others; and by geography. Driven by the rising cardiovascular disease burden, an aging population, AI-enabled low-dose imaging, and ongoing cath-lab expansion, coronary angiography devices remain essential infrastructure for the diagnosis and treatment of coronary artery disease.

Coronary Angiography Devices Market Key Growth Drivers

• The rising burden of cardiovascular disease is the primary growth driver, with the World Health Organization estimating about 19.8 million CVD deaths in 2022, or 32% of global mortality, and the CDC reporting 702,880 heart disease deaths in the United States in 2022.
• The aging global population is expanding the pool of patients with coronary artery disease, with roughly 10% of the world population, about 800 million people, now aged 65 and older, a share exceeding 20% in Europe and East Asia.
• Patient and clinician preference for minimally invasive procedures, which offer shorter hospital stays, faster recovery, and lower complication risk than open surgery, is sustaining rising angiography and PCI volumes.
• Technological advancements, including AI-based image reconstruction, ultra-low-dose imaging, 3D and rotational angiography, robotic-assisted navigation, and hybrid angiography-CT systems, are improving diagnostic accuracy and driving system upgrade cycles.
• Continued cath-lab expansion and healthcare infrastructure investment, particularly across China, India, and other Asia-Pacific markets, are broadening access to coronary angiography in tier-2 and tier-3 cities.
• Recurring demand for high-volume consumables such as diagnostic catheters, guidewires, balloons, and vascular closure devices, together with service contracts and software upgrades, provides manufacturers with durable revenue streams.
• The convergence of rising disease burden, demographic aging, technological innovation, and infrastructure investment is expected to sustain steady growth in the market through 2034.

Key Companies in Coronary Angiography Devices Market

The competitive landscape is led by the following active manufacturers:

• GE HealthCare
• Siemens Healthineers
• Koninklijke Philips N.V.
• Medtronic
• Abbott Laboratories
• Boston Scientific Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• Cardinal Health
• Canon Medical Systems Corporation

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Coronary Angiography Devices Market Size

The following snapshot summarizes the principal report metrics for the Coronary Angiography Devices market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Coronary Angiography Devices Market

Market Drivers

Rising Prevalence of Cardiovascular Diseases

The most powerful driver of the Coronary Angiography Devices market is the escalating prevalence of cardiovascular disease. Sedentary lifestyles, unhealthy diets, smoking, obesity, diabetes, hypertension, and chronic stress have accelerated the incidence of coronary artery disease, valvular heart disease, and heart failure, creating a vast patient pool that requires diagnostic evaluation. The World Health Organization estimated about 19.8 million CVD deaths globally in 2022, accounting for 32% of total mortality, with more than three-quarters occurring in low- and middle-income countries, while the CDC reported that heart disease claimed 702,880 lives in the United States in 2022, equivalent to one death every 33 seconds. Invasive coronary angiography remains the gold standard for definitive diagnosis and therapeutic decision-making in coronary artery disease, so this burden translates directly into rising procedure volumes and demand for angiography systems, catheters, guidewires, balloons, and closure devices across the forecast period. 

Aging Global Population

The aging global population is a powerful and durable growth catalyst. As life expectancy rises, particularly in developed economies, the prevalence of age-related cardiovascular conditions increases sharply. According to the World Population Data Sheet (September 2024), about 10% of the global population, roughly 800 million people, is now aged 65 and older, a share that exceeds 20% in regions such as Europe and East Asia. Older adults are disproportionately affected by coronary artery disease and related conditions, fueling demand for diagnostic angiography procedures, cath-lab expansion, and advanced device adoption. This demographic trend supports long-term procedural growth and steady demand not only for capital angiography systems but also for high-margin consumables such as diagnostic catheters, contrast injectors, and hemostasis devices through 2034.

Preference for Minimally Invasive Procedures

Patients and healthcare professionals increasingly favor minimally invasive procedures over traditional open surgery, and coronary angiography is a core example. The approach offers shorter hospital stays, faster recovery, reduced risk of complications and infection, and less patient discomfort, while allowing diagnosis and treatment, such as balloon angioplasty or stent placement, within a single catheterization session. Radial-access techniques and improved vascular closure devices are further shortening recovery and enabling same-day discharge in appropriate patients, which encourages hospitals and diagnostic centers to expand their cath-lab capacity. As clinical guidelines and reimbursement continue to favor catheter-based diagnosis and intervention, procedure volumes and the associated demand for devices and consumables rise in step.

Technological Advancements in Imaging and Devices

Continuous innovation is reshaping the market by improving diagnostic precision, safety, and efficiency. Advanced imaging technologies, including 3D and rotational angiography, enhanced fluoroscopy, flat-panel detectors, and AI-powered image reconstruction, reduce procedure time and lower radiation and contrast exposure for patients and clinicians. Improved catheter and guidewire designs offer greater flexibility and navigability through complex vessels, while hybrid angiography-CT suites, such as Canon Medical's Alphenix 4D CT with Aquilion ONE / INSIGHT Edition cleared by the FDA in late 2025, allow diagnosis, planning, and intervention without moving the patient. Integration with intravascular imaging (IVUS and OCT) and physiology (FFR and iFR) lets cardiologists assess complex lesions with greater confidence. These advances drive replacement cycles and premium-system adoption across the forecast period.

Cath-Lab Expansion and Healthcare Infrastructure Investment

Investment in cardiac catheterization infrastructure is broadening access to coronary angiography, especially in emerging markets. In China, the Healthy China 2030 plan and rapid cath-lab expansion across tier-2 and tier-3 cities, supported by reimbursement reforms, are lifting procedure volumes in a country with more than 300 million people living with cardiovascular disease. In India, government schemes such as Ayushman Bharat and a growing number of cath labs in metropolitan and tier-2 cities are expanding access to interventional cardiology. Mature markets, including Germany, with about 900,000 coronary angiographies annually, continue to modernize with low-dose, AI-enabled systems and hybrid operating rooms. This public and private investment creates sustained demand for both capital equipment and recurring consumables.

Recurring Consumables and Service-Driven Revenue Models

The structure of the market itself supports growth. Every angiography procedure requires single-use disposables, including diagnostic catheters, guidewires, balloons, and vascular closure devices, creating a steady, high-volume, recurring revenue stream that is less cyclical than capital equipment. Angiography systems, which cost from several hundred thousand to millions of USD per unit, in turn generate recurring revenue through service contracts, software upgrades, and predictive maintenance programs. Shimadzu's SHIMADZU Connected digital platform and SMILE Guard predictive maintenance solution, launched in March 2024, illustrate an industry shift toward service-oriented and software-led business models that improve system uptime and deepen customer relationships.

Strategic Partnerships, Acquisitions, and AI Integration

Active portfolio building and collaboration are accelerating innovation and market reach. Teleflex announced the acquisition of BIOTRONIK's Vascular Intervention business; Canon Medical has partnered with AI cardiac imaging companies including Cleerly; and Medtronic co-promotes CathWorks' AI-based FFRangio system, which derives FFR values from angiographic data without a pressure wire and received CE Mark under the EU MDR in May 2024. Venture-backed firms such as Cleerly, with more than USD 248 million raised, and Caristo Diagnostics are advancing AI analysis of coronary imaging. Together, these moves expand the value delivered per procedure, support software-driven recurring revenue, and strengthen the competitive position of established players across the forecast period.

Market Restraints

Despite steady momentum, the Coronary Angiography Devices market faces material constraints. The high cost of advanced angiography systems and related procedures is a significant financial barrier for healthcare facilities, especially in developing economies, and the cost of consumables adds to the overall expense for patients and payers. Stringent and lengthy regulatory approval processes raise R&D costs, delay product launches, and create high barriers to entry for new companies. A shortage of skilled professionals, including interventional cardiologists and cath-lab technicians, limits the adoption of these devices in some regions. The market also faces competition from non-invasive diagnostic alternatives such as CT angiography (CTA) and MR angiography, which can reduce the need for diagnostic invasive procedures in selected patients. Radiation exposure to patients and clinicians during X-ray-based procedures remains a persistent safety concern that drives investment in dose-reduction technology but adds cost and training requirements. Recent United States tariff actions on selected imports and components, including X-ray tubes, generators, and catheter subcomponents, raise landed costs, compress OEM and distributor margins, and can delay hospital capital purchases and supply chains in the near term. Together, these cost, regulatory, workforce, competitive, and trade barriers temper the pace of growth, even as the underlying drivers of cardiovascular disease burden, demographic aging, and technological innovation remain firmly intact.

Coronary Angiography Devices Market Segment Analysis

The Coronary Angiography Devices market is segmented by product (angiography systems, angiography catheters, vascular closure devices (VCDS), angiography balloons, angiography guidewires, and others), technology (X-ray angiography, CT angiography, MR angiography, and others), application (diagnostics and therapeutics), end-user (hospitals, diagnostic centers, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product

Dominant Subsegment: Angiography Systems. 

The angiography systems segment accounted for 25% of the Coronary Angiography Devices market in 2025. Angiography systems lead the product segment because they are the fundamental and most expensive component of a cardiac catheterization lab, representing a significant capital investment for hospitals and cath-lab operators, with each unit costing several hundred thousand to millions of USD. Beyond upfront sales, systems generate recurring revenue through service contracts, software upgrades, and predictive maintenance programs, such as Shimadzu's SMILE Guard, which reinforces their share of market value. Continuous innovation, including flat-panel detectors, AI-assisted image processing, low-dose imaging, and hybrid angiography-CT suites, sustains replacement and upgrade demand. At the same time, consumables, including catheters, guidewires, and balloons, hold a significant and growing share because every procedure requires disposables, and vascular closure devices are expanding with the adoption of radial and femoral access techniques. Nonetheless, the high unit value and recurring service revenue of angiography systems secure the segment's leadership across the forecast period.

By Technology

Dominant Subsegment: X-Ray Angiography. 

The X-ray angiography segment accounted for 52% of the Coronary Angiography Devices market in 2025. X-ray angiography remains the clinical gold standard for real-time visualization of the coronary arteries and for guidance during interventions such as percutaneous coronary intervention (PCI) and stent placement. It is indispensable in every cath lab, and ongoing advances, including digital flat-panel detectors, ultra-low-dose imaging, AI-assisted reconstruction, and 3D and 4D imaging, reinforce its position. X-ray angiography also serves as the central platform integrating adjunct modalities such as fractional flow reserve (FFR), intravascular ultrasound (IVUS), and optical coherence tomography (OCT), while rising investment in cath-lab infrastructure continues to drive adoption. CT angiography is growing as a non-invasive alternative and planning tool, supported by AI-based plaque analysis, and MR angiography serves selected patients where radiation avoidance is a priority. Nonetheless, the real-time guidance and therapeutic compatibility of X-ray angiography secure its leadership across the forecast period.

By Application

Dominant Subsegment: Diagnostics. 

The diagnostics segment accounted for 58% of the Coronary Angiography Devices market in 2025. Diagnostics leads the application segment because accurate diagnosis of the location and severity of coronary blockages is the prerequisite for every therapeutic intervention, and invasive coronary angiography is the gold-standard tool for confirming coronary artery disease. The sheer volume of diagnostic procedures exceeds that of therapeutic ones, since a patient may undergo several diagnostic angiographies over a lifetime of disease management while receiving an intervention only once. Growing awareness of cardiovascular disease and a focus on early detection are increasing screening of at-risk populations. The diagnostic market also spans not only angiography systems but also dedicated diagnostic catheters and complementary imaging and physiology tools such as IVUS, OCT, and FFR. While therapeutics, including angioplasty and stent placement, are supported by rising PCI volumes and the use of balloons, guidewires, and closure devices, the breadth of the diagnostic portfolio and its central role in the care pathway secure the segment's leadership across the forecast period.

By End-User

Dominant Subsegment: Hospitals. 

The hospitals segment accounted for 68% of the Coronary Angiography Devices market in 2025. Hospitals are the leading end-user because they are the primary and best-equipped facilities for complex cardiovascular care, with dedicated cardiac catheterization laboratories and hybrid operating rooms that require capital investment beyond the reach of smaller clinics and diagnostic centers. They treat the highest volume of patients with severe cardiovascular disease, especially emergencies such as heart attacks and acute coronary syndromes, and they employ the full spectrum of interventional cardiologists, surgeons, and trained technicians required for both diagnostic and therapeutic angiography. Hospitals are also the main buyers of angiography systems and the high-volume consumables that accompany every procedure. Diagnostic centers and ambulatory settings are expanding as outpatient diagnostic angiography and same-day discharge gain acceptance, but the combination of advanced infrastructure, patient volume, and specialized expertise secures the hospital segment's leadership across the forecast period.

Coronary Angiography Devices Market Region Analysis

Dominant Region: North America

North America accounted for 35% of the global Coronary Angiography Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high burden of cardiovascular disease, a rapidly aging population, sophisticated healthcare infrastructure, strong regulatory and reimbursement support, and consistent adoption of cutting-edge technologies such as AI-integrated systems, low-dose imaging, and hybrid operating rooms. The United States accounts for the large majority of regional revenue, reflecting its outsized role in innovation and consumption. The market is characterized by a strong emphasis on technological innovation and by robust, consistent demand for single-use consumables such as catheters and guidewires. Most leading manufacturers, including GE HealthCare, Medtronic, Abbott Laboratories, Boston Scientific, and Cardinal Health, are headquartered or have major operations in the region, and a favorable regulatory and reimbursement landscape anchors continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Coronary Angiography Devices market. The region is home to a large and rapidly aging population, and the adoption of Western lifestyles has driven a sharp rise in cardiovascular disease, diabetes, and hypertension, creating a massive patient pool for diagnostic and therapeutic cardiac procedures. China is the largest market in the region, with more than 300 million people living with cardiovascular disease, including more than 11 million with coronary heart disease, and the Healthy China 2030 plan is modernizing healthcare infrastructure and expanding cath labs across tier-2 and tier-3 cities. India is projected to be the fastest-growing country market, supported by rising healthcare spending, a growing number of cath labs, and schemes such as Ayushman Bharat, while Japan maintains strong demand as a mature, highly aged market, and Australia and South Korea contribute steady growth. New hospital construction, rising disposable incomes, and public and private healthcare investment position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 35% of the global Coronary Angiography Devices market revenue in 2025. The United States dominates on the strength of its cardiovascular disease burden, aging population, advanced healthcare infrastructure, and favorable reimbursement, while rapid adoption of AI-integrated, low-dose, and hybrid angiography systems reinforces its leadership. Canada and Mexico contribute through expanding cardiac care capacity.

Europe

Europe is a large and advanced regional market, supported by a high cardiovascular disease burden, widespread cath-lab capacity, and steady upgrades to low-dose, AI-enabled X-ray angiography systems and hybrid operating suites. Germany is the volume leader with some of the highest per-capita angiography and PCI rates in Europe, the United Kingdom benefits from the NHS focus on high-volume minimally invasive procedures, France is advancing physiology- and imaging-guided PCI, and Italy and Spain sustain a robust base of interventional procedures. Cath-lab modernization and growing adoption of intravascular imaging support mid-single-digit growth across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a rapidly aging population, rising prevalence of cardiovascular disease, diabetes, and hypertension, and large public and private healthcare investment across China, Japan, India, Australia, and South Korea. China's cath-lab expansion under Healthy China 2030, India's rapid growth supported by Ayushman Bharat, and Japan's advanced, high-quality device market are accelerating regional adoption of angiography systems and consumables.

Rest of World

The Rest of World region, spanning South America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital and cardiac-care infrastructure, rising awareness of cardiovascular disease, and growing investment in cath labs are gradually broadening access to coronary angiography, while affordability and access to trained interventional cardiologists remain key factors shaping adoption.

Coronary Angiography Devices Market Competitive Landscape

The Coronary Angiography Devices market is classified as Consolidated. A group of multinational imaging leaders, including GE HealthCare, Siemens Healthineers, and Koninklijke Philips N.V., dominates the market for high-value angiography systems, while Medtronic, Abbott Laboratories, and Boston Scientific Corporation lead the consumables segment of catheters, guidewires, and balloons. Terumo Corporation, B. Braun Melsungen AG, Cardinal Health, and Canon Medical Systems Corporation compete through specialized catheter, closure, and imaging portfolios, while smaller companies focus on niche segments or form strategic partnerships, and high regulatory and capital barriers favor established players.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Consolidated, with a few multinational medical technology companies holding a significant share, and smaller players focusing on niche product segments or partnerships.
• Leading players: GE HealthCare, Siemens Healthineers, and Koninklijke Philips N.V. lead angiography systems; Medtronic, Abbott Laboratories, and Boston Scientific Corporation lead consumables.
• Geographic reach: Leaders operate global sales, service, and manufacturing networks that support cath-lab installations and recurring consumable supply across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players offer integrated portfolios spanning angiography systems, catheters, guidewires, balloons, closure devices, and adjunct imaging and physiology tools.
• Technology integration: AI-based image processing, low-dose imaging, robotics, 3D imaging, and hybrid angiography-CT systems are central to competitive differentiation and improved workflow.
• Strategic partnerships: Collaborations with AI and imaging specialists, such as Canon Medical's work with Cleerly and Medtronic's co-promotion of CathWorks' FFRangio, extend clinical capability and reach.
• M&A activity: Active portfolio building, including Teleflex's announced acquisition of BIOTRONIK's Vascular Intervention business, is consolidating the consumables landscape.
• Manufacturing capabilities: Scale, regulatory track record, quality systems, and resilient supply chains, including tariff-driven sourcing adjustments, are key competitive moats.
• Innovation focus: AI-assisted intracoronary imaging, multimodal intravascular imaging (IVUS/OCT), angiography-derived physiology, service-oriented digital platforms, and dose-reduction technologies.

Coronary Angiography Devices Market Recent Developmental Activities

In November 2025, Canon Medical Systems Corporation received FDA clearance for its Alphenix 4D CT with Aquilion ONE / INSIGHT Edition, a hybrid system integrating angiography and CT in a single suite. Strategic significance: Lets clinicians complete diagnostic imaging, planning, intervention, and post-procedure assessment without moving the patient, shortening procedure time.

In 2025, Teleflex Incorporated announced the acquisition of BIOTRONIK's Vascular Intervention business. Strategic significance: Expands Teleflex's interventional cardiology and vascular device portfolio and signals continued consolidation in consumables.

In 2024 and 2025, Canon Medical Systems Corporation entered partnerships with AI-driven cardiac imaging companies, including Cleerly, to strengthen coronary imaging analysis. Strategic significance: Builds software and AI capability around Canon's imaging hardware and supports higher diagnostic accuracy.

In October 2024, Shimadzu Corporation launched the SCORE Opera (Trinias Series) with SMART Voice, a voice-activated angiography system that enables hands-free control of imaging functions. Strategic significance: Improves workflow efficiency and reduces procedural strain for operators.

In October 2024, Gentuity received FDA 510(k) clearance for its HF-OCT Imaging System with the Vis-Rx micro-imaging catheter, the first high-frequency OCT platform cleared for both pre- and post-PCI vessel imaging. Strategic significance: Improves diagnostic precision and post-stenting outcomes and expands intravascular imaging use alongside angiography.

In September 2024, GE HealthCare received FDA approval for Flyrcado, a PET myocardial perfusion imaging agent. Strategic significance: Extends GE HealthCare into pharmaceutical diagnostics and diversifies from hardware within cardiac diagnostics.

In May 2024, CathWorks received CE Mark under the EU Medical Device Regulation for its FFRangio System, with Medtronic co-promotion, enabling full commercialization in Europe. Strategic significance: Uses AI and angiographic data to derive FFR without invasive pressure wires, facilitating physiological assessment during angiography.

In March 2024, Shimadzu Corporation launched SHIMADZU Connected, a service-oriented digital platform for its angiography and X-ray systems, including the SMILE Guard predictive maintenance solution. Strategic significance: Reflects an industry shift toward recurring revenue from service contracts, software upgrades, and predictive analytics while minimizing system downtime.

Coronary Angiography Devices Market Segmentation

Coronary Angiography Devices Market by Product

• Angiography Systems
• Angiography Catheters
• Vascular Closure Devices (VCDs)
• Angiography Balloons
• Angiography Guidewires
• Others

Coronary Angiography Devices Market by Technology

• X-Ray Angiography
• CT Angiography
• MR Angiography
• Others

Coronary Angiography Devices Market by Application

• Diagnostics
• Therapeutics

Coronary Angiography Devices Market by End-User

• Hospitals
• Diagnostic Centers
• Others

Coronary Angiography Devices Market by Geography

• North America Coronary Angiography Devices Market

• United States Coronary Angiography Devices Market Size in USD million (2023-2034)
• Canada Coronary Angiography Devices Market Size in USD million (2023-2034)
• Mexico Coronary Angiography Devices Market Size in USD million (2023-2034)
• Europe Coronary Angiography Devices Market
• Germany Coronary Angiography Devices Market Size in USD million (2023-2034)
• United Kingdom Coronary Angiography Devices Market Size in USD million (2023-2034)
• France Coronary Angiography Devices Market Size in USD million (2023-2034)
• Italy Coronary Angiography Devices Market Size in USD million (2023-2034)
• Spain Coronary Angiography Devices Market Size in USD million (2023-2034)
• Rest of Europe Coronary Angiography Devices Market Size in USD million (2023-2034)
• Asia-Pacific Coronary Angiography Devices Market
• China Coronary Angiography Devices Market Size in USD million (2023-2034)
• Japan Coronary Angiography Devices Market Size in USD million (2023-2034)
• India Coronary Angiography Devices Market Size in USD million (2023-2034)
• Australia Coronary Angiography Devices Market Size in USD million (2023-2034)
• South Korea Coronary Angiography Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Coronary Angiography Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) Coronary Angiography Devices Market
• Middle East Coronary Angiography Devices Market Size in USD million (2023-2034)
• Africa Coronary Angiography Devices Market Size in USD million (2023-2034)
• South America Coronary Angiography Devices Market Size in USD million (2023-2034)

Coronary Angiography Devices Market Recent Industry Trends and Milestones (2023-2026)

Coronary Angiography Devices Market Startup Funding and Investment Trends

Investment in the Coronary Angiography Devices ecosystem has concentrated on AI-driven analysis of coronary imaging, alternative contrast delivery, and image-guided physiology. The following companies illustrate recent funding and investment activity and technology focus.

Capital is flowing toward companies that apply AI to coronary imaging and reduce contrast and radiation burden. Cleerly, with more than USD 248 million raised, has built an FDA-cleared AI platform for coronary CT angiography that quantifies and characterizes plaque and stenosis, while Caristo Diagnostics, with USD 16.3 million in Series A funding, is developing CaRi-Heart technology to detect coronary inflammation from CT angiography scans. Angiodroid, which raised USD 10.2 million in a Series B round, offers a carbon dioxide injector that uses CO2 as a contrast medium for peripheral and coronary angiography. Collectively, these investments signal conviction that AI-enabled imaging, software-led recurring revenue, and safer contrast and dose strategies will shape the next phase of competitive advantage in the global Coronary Angiography Devices market.

Key Takeaways from the Coronary Angiography Devices Market Report Study

• Market size analysis for the current Coronary Angiography Devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global Coronary Angiography Devices market.
• Various opportunities available for competitors in the Coronary Angiography Devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Coronary Angiography Devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Coronary Angiography Devices market growth in the future?

Target audience who can benefit from this Coronary Angiography Devices market report study 

• Coronary Angiography Devices product providers
• Research organizations and consulting companies
• Coronary Angiography Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Coronary Angiography Devices  
• Various end-users who want to know more about the Coronary Angiography Devices market and the latest technological developments in the Coronary Angiography Devices market.